Study S001955

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07139548
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 600
Start: 2025-08-31
Primary completion: 2026-12-01
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Conditions: T2DM
Interventions: DRUG:RAY1225; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg) [Baseline,36 Week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.